Objective: To investigate the technical periprocedural and midterm outcomes of endovascular repairs with multibranched endovascular repair or iliac branch devices combined with a new self-expanding covered stent.

Methods: The COvera in BRAnch registry is a physician-initiated, multicenter, ambispective, observational registry (ClinicalTrials.gov Identifier: NCT04598802) enrolling patients receiving a multibranched endovascular repair or iliac branch devices procedure mated with Bard Covera Plus (Tempe, AZ) covered stent, designed to evaluate the outcomes of the covered stent mated with patient-specific and off-the-shelf branched stent graft. Primary end points were technical success, branch instability, and freedom from aortic and branch-related reintervention within 30 days and at follow-up. Preoperative characteristics, comorbidities, and outcomes definitions were graded according to the Society for Vascular Surgery reporting standards.

Results: Two hundred eighty-four patients (76 years; range, 70-80 years; 79% males) in 24 centers were enrolled for a total of 708 target vessels treated. The covered stents were mated with an off-the-shelf graft in 556 vessels (79%) and a custom-made graft in 152 (21%). Three hundred seven adjunctive relining stents in 277 vessels (39%) were deployed, of which 116 (38%) were proximal, 66 (21%) intrastent, and 125 (41%) distal. Adjunctive relining stent placement was more frequent when landing in a vessel branch instead of the main trunk (59% vs 39%; P = .031), performing a percutaneous access (49% vs 35%; P < .001), using a stent with a diameter of 8 mm or greater (44% vs 36%; P = .032) and a length of 80 mm or greater (65% vs 55%; P = .005), when a post-dilatation was not performed (45% vs 29%; P < .001) and when an inner branch configuration was used (55% vs 35%; P < .001). Perioperative technical bridging success was 98%. Eight patients (3%) died in the perioperative period. Two deaths (1%) were associated with renal branch occlusion followed by acute kidney injury and paraplegia. Follow-up data were available for 638 vessels (90%) at a median of 32 months (Q1, Q3, 21, 46). Branch instability was reported in 1% of branches. Forty-six patients (17%) died during follow-up, nine (3%) of them owing to aortic-related causes. Primary patency rates at 1, 2, and 3 years were 99% (581/587), 99% (404/411), and 97% (272/279), respectively. Branch instability was associated with patient-specific devices (9% vs 4%; P = .014) and intrastent adjunctive stent placement (12% vs 2%; P = .003), especially when a bare metal balloon-expandable stent was used (25% vs 3%; P < .001).

Conclusions: The use of this new self-expanding covered stent mated with branched endografts proved to be safe and feasible with high technical procedural success rates. Low rates of branch instability were observed at midterm follow-up. Comparative studies with other commercially available covered stents are warranted.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jvs.2023.02.007DOI Listing

Publication Analysis

Top Keywords

covered stent
16
branch instability
16
p < 001
12
stent
10
branch
10
branched stent
8
multibranched endovascular
8
endovascular repair
8
repair iliac
8
iliac branch
8

Similar Publications

Endovascular stent graft repair was developed to minimize the invasiveness of open surgery for thoracic and abdominal aortic diseases. This approach involves covering the diseased segment with a stented artificial graft. However, in thoracic endovascular aortic repair (TEVAR) for aortic arch diseases, special consideration is needed to preserve the aortic arch vessels.

View Article and Find Full Text PDF

Purpose: This study aims to develop and implement an economic evaluation using a micro-costing approach to provide a precise and transparent analysis of the direct costs of cystoscopic procedures in Korean hospitals. The study seeks to identify key cost components and evaluate whether current reimbursement rates accurately reflect these direct costs.

Materials And Methods: Significant variations in cost items were identified across different studies.

View Article and Find Full Text PDF

Staged Hybrid Management of a Mycotic Ascending Aortic Pseudoaneurysm.

Ann Thorac Surg Short Rep

December 2024

Division of Pediatric and Adult Congenital Cardiothoracic Surgery, Geisinger Medical Center, Danville, Pennsylvania.

Ascending aortic pseudoaneurysm may pose significant risk for reoperative repair. We describe an 18-year-old man who presented with bacteremia and a large, mycotic ascending aortic pseudoaneurysm 3 months after redo cardiac surgery. A covered stent graft sealed the pseudoaneurysm neck and facilitated safe reentry into the mediastinum.

View Article and Find Full Text PDF

A 54-year-old man underwent right S6 segmentectomy for right lung cancer. After discharge, he presented with fever, hemoptysis, and cough, and computed tomography showed an intermediate bronchus fistula. Because direct closure or bronchoplasty was challenging, a Dumon (Novatech) stent was inserted directly into the fistula from the surgical field and covered with an autologous pericardial patch, pedicled mediastinal fat, and intercostal muscle.

View Article and Find Full Text PDF

Purpose: The AVeNEW Post-Approval Study (AVeNEW PAS) follows upon results from the AVeNEW IDE clinical trial and was designed to provide additional clinical evidence of safety and effectiveness using the Covera™ Vascular Covered Stent to treat arteriovenous fistula (AVF) stenoses in a real-world hemodialysis patient population.

Materials And Methods: One hundred AVF patients were prospectively enrolled at 11 clinical trial sites in the USA and treated with the covered stent after angioplasty of a clinically significant target stenosis. The primary safety outcome was freedom from any adverse event that suggests the involvement of the AV access circuit evaluated at 30 days.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!